New Atlantis Labs is pioneering the first marine-only, AI-native platform that transforms raw data into revenue-generating products. Their mission is to unlock the economic potential of marine biological resources to ensure their long-term protection, benefiting Marine Protected Areas (MPAs), governments, local communities, industries, and investors. The company addresses the urgent need for sustainable funding models for MPAs while providing tools for protein discovery, ecological metrics, and scenario generation to facilitate informed decision-making in marine ecosystem management.

10x Genomics is a biotechnology company that specializes in advanced genomic technologies, particularly in single-cell sequencing and spatial genomics. Their innovative platforms, such as Chromium and Visium, enable researchers to conduct high-resolution analyses of biological samples, revealing cellular diversity and complex tissue structures. With a strong focus on affordability and performance, 10x Genomics has established a significant presence in the life sciences market, supported by over 8,200 publications utilizing their products. Their commitment to advancing human health through cutting-edge technology positions them as a leader in the genomics field.

23andMe is a human genome research company that provides DNA genetic testing services for health and ancestry. Their key products include the Ancestry Service and Health + Ancestry Service, which offer comprehensive insights into genetic data and health predispositions. The company differentiates itself with a robust platform that combines ancestry analysis with health-related genetic insights, making it a leader in the personal genomics market. With over 12 million kits sold, 23andMe has established a significant presence in the biotech and health care industries, appealing to both consumers and researchers.

3Helix is a biotechnology research center. They provide pathology, biomechanics, cell biology, and regenerative medicine services. An online inquiry form is available on the company's website.

A-Alpha Bio is a biotechnology company that leverages synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Their experimental platform, Alpha Seq, allows for the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously, while their computational platform, Alpha Bind, predicts binding strength from sequence using the world’s largest protein-protein interaction database. A-Alpha Bio collaborates with leading pharmaceutical companies to inform the discovery and development of novel therapeutics, positioning itself as a key player in therapeutic discovery and optimization.

Abbott is a global healthcare leader engaged in pharmaceuticals and manufacturing healthcare products, with a focus on innovative technologies that improve patient outcomes. The company is known for its groundbreaking products such as the Free Style Libre continuous glucose monitoring systems, which revolutionize diabetes care, and its rapid COVID-19 testing solutions. Abbott's commitment to sustainability and access aims to reach one in three people globally by 2030, positioning it as a key player in the healthcare market with significant traction in various therapeutic areas.

AbbVie is a biopharmaceutical company that develops pharmaceuticals and medical devices. The company provides products and services to therapeutic areas including immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology advancing treatments across various therapeutic areas.

Abcellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. Abcellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. Abcellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development.

Abdera Therapeutics Inc. is a precision oncology company focused on developing next-generation targeted radiation therapies. Utilizing a proprietary modular technology platform, the company aims to deliver radioisotopes that selectively destroy tumor cells while sparing healthy cells. Abdera is committed to rapidly developing therapies for cancer patients with limited treatment options, and is currently advancing its pipeline with plans to initiate a Phase 1 clinical trial for small cell lung cancer and large cell neuroendocrine carcinoma. With a strong team of experts in drug development and a focus on innovative cancer treatments, Abdera is positioned to make a significant impact in the oncology market.

Absci is a generative AI drug creation company focused on creating better biologics for patients faster. By leveraging deep learning AI and synthetic biology, Absci has developed an Integrated Drug Creation Platform that enables the design and validation of novel biologics, significantly reducing the time and cost associated with traditional drug discovery methods. The company partners with leaders in pharma, tech, and academia to tackle challenging targets, aiming to deliver life-changing medicines efficiently. With over 20 active programs and state-of-the-art facilities in multiple locations, Absci is positioned to revolutionize the biologics landscape and improve patient outcomes.

Active Motif is a global company built by scientists, for scientists, specializing in epigenetics and gene regulation research. With over two decades of experience, they develop innovative technologies, products, and services that cater to the needs of researchers in this field. Their offerings include a comprehensive range of assays, kits, and services designed to facilitate advanced research in chromatin biology and epigenetics. Active Motif differentiates itself through its commitment to quality, collaboration, and a strong focus on customer support, positioning itself as a leader in the epigenetics market.

Adaptive Biotechnologies is a commercial-stage company pioneering Immune Medicine by leveraging the adaptive immune system to enhance disease diagnosis and treatment. Their flagship product, clono SEQ®, is an FDA-authorized clinical diagnostic test for detecting and monitoring minimal residual disease in blood cancer patients. The company focuses on translating immune data into actionable insights for clinical applications, thereby positioning itself as a leader in the emerging field of immune-driven medicine. Founded in 2009 and based in Seattle, Adaptive Biotechnologies is at the forefront of innovation in immunology, with a strong commitment to improving patient outcomes through advanced diagnostics and therapeutics.